

Funder	Project Title	Funding	Institution
Department of Defense - Army	Metabolic signature of antipsychotics used in the treatment of autism	\$0	University of Cincinnati
Autism Science Foundation	Human Clinical Trial of IGF-1 in Children with Idiopathic ASD	\$25,000	Icahn School of Medicine at Mount Sinai
Autism Speaks	Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders	\$99,971	Indiana University
National Institutes of Health	3/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$200,372	University of California, Los Angeles
National Institutes of Health	4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$168,533	Yale University
National Institutes of Health	1/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$1	Indiana University-Purdue University Indianapolis
National Institutes of Health	2/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD	\$171,791	Seattle Children's Hospital